The Zacks Analyst Blog Highlights Exxon Mobil, Bristol-Myers Squibb, Chubb and Hamilton Beach Brands

For Immediate ReleaseChicago, IL – April 3, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Exxon Mobil Corp. XOM, Bristol-Myers Squibb Co. BMY, Chubb Ltd. CB and Hamilton Beach Brands Holding Co. HBB.Here are highlights from Wednesday’s Analyst Blog:Top Research Reports for Exxon Mobil, Bristol Myers & ChubbThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corp., Bristol-Myers Squibb Co. and Chubb Ltd., as well as a micro-cap stock Hamilton Beach Brands Holding Co.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Down Again on "Liberation Day"Today's Featured Research ReportsShares of Exxon Mobil have gained +3.2% over the past year, against the Zacks Oil and Gas - Integrated - International industry's gain of +5.5%. The company's high-value assets in the Permian Basin and Guyana drive robust production growth, doubling upstream earnings since 2019. The Pioneer acquisition and Guyana ramp-up have enhanced profitability, while robust structural savings strengthen resilience.With a lower exposure to debt capital, XOM supports steady cash flows, dividends, buybacks and investments in high-return projects. Expansion in low-carbon tech, including Baytown's hydrogen facility, positions it for future growth.Yet refining margins are pressured due to global capacity increases, with refining profits softening. The refining margin pressure intensifies the reliance on upstream operations, which is vulnerable to fluctuating oil and gas prices. Commodity price volatility challenges profitability, especially as crude prices dipped in the fourth quarter.(You can read the full research report on Exxon Mobil here >>>)Bristol-Myers Squibb's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+19.8% vs. -8.7%). The company's newer drugs like Reblozyl, Breyanzi, Yervoy, Camzyos and Opdualag maintain momentum for the company. Label expansion of blockbuster oncology drug Opdivo should fuel growth. Growth in blockbuster drug Eliquis is another positive.Nevertheless, the recent acquisitions of Mirati, Karuna and RayzeBio should strengthen and diversify its portfolio. Bristol Myers' efforts to streamline operations should boost the bottom line. The company is encouraging efforts to boost top-line growth.However, the outlook for 2025 is weak. Generic competition for Revlimid, Pomalyst, Sprycel and Abraxane is adversely impacting revenue growth. While the performance of new drugs is encouraging, they will take some time to make a significant contribution to the top line.(You can read the full research report on Bristol-Myers Squibb here >>>)Shares of Chubb have gained +19.8% over the past year against the Zacks Insurance - Property and Casualty industry's gain of +25.1%. The company's suite of compelling products as well as services, focus on capitalizing on the potential of middle-market businesses and investments in various strategic initiatives pave the way for long-term growth.Several distribution agreements have expanded its network, boosting its market presence. An impressive inorganic growth story helps to achieve a higher long-term return on equity. Chubb boasts a strong capital position with sufficient cash generation capabilities that ensure steady payouts to investors.Chubb expects the quarterly adjusted net investment income to have a run rate between $1.67 billion and $1.75 billion over the next six months. However, exposure to catastrophe loss induces underwriting volatility. Escalating expenses weigh on margin expansion.(You can read the full research report on Chubb here >>>)Hamilton Beach Brands' shares have outperformed the Zacks Household Appliances industry over the year-to-date period (+18.7% vs. -17.7%). This microcap company with market capitalization of $268.41 million achieved a record gross margin of 26% in 2024, up 300 bps year over year, driven by lower costs, improved mix and pricing discipline.Operating profit rose 23.1% to $43.2 million. A strong cash flow of $65.4 million enabled debt elimination, ending with a net cash position of $0.6 million. HBB expanded into high-margin healthcare with HealthBeacon, targeting more than 50% patient growth in 2025. Product innovation, including premium offerings and e-commerce expansion, is driving market share gains.U.S. consumer sales rose 3.6%, with strong growth in Mexico and commercial blender placements. Proactive tariff mitigation and supply-chain diversification protect margins. The 2025 guidance includes mid-single-digit revenue growth, operating profit outpacing sales and $40-$50 million in free cash flow.(You can read the full research report on Hamilton Beach Brands here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                      https://www.zacks.com                                                  Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Chubb Limited (CB): Free Stock Analysis Report Hamilton Beach Brands Holding Company (HBB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks